Background/Aim: Trabectedin and eribulin are widely used for the treatment of soft-tissue sarcoma (STS). Previously it was shown that the baseline neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of eribulin for STS. However, prognostic factors for trabectedin on STS have not been identified to date. Patients and Methods: We conducted a retrospective study of data collected prospectively from 39 patients treated with trabectedin for recurrent or metastatic STS between October 2012 and December 2019. To determine the predictive factors of overall survival (OS) and progression-free survival (PFS), univariate and multivariate analyses were performed. Results: Age ≥40 (HR=0.33, 95% CI=0.15-0.71; p=0.0050) and changes in NLR (ΔNLR) <0.5 (HR=2.40, 95% CI-1.01-5.72; p=0.048) were independent factors predictive of longer OS. In addition, age ≥40 (HR=0.23, 95% CI=0.10-0.52; p<0.001) was an independent predictor of longer PFS. Conclusion: Changes in NLR and age ≥40 years were able to predict the efficacy of trabectedin for STS. Copyright 2021, International Institute of Anticancer Research.
Background/Aim: Trabectedin and eribulin are widely used for the treatment of soft-tissue sarcoma (STS). Previously it was shown that the baseline neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of eribulin for STS. However, prognostic factors for trabectedin on STS have not been identified to date. Patients and Methods: We conducted a retrospective study of data collected prospectively from 39 patients treated with trabectedin for recurrent or metastatic STS between October 2012 and December 2019. To determine the predictive factors of overall survival (OS) and progression-free survival (PFS), univariate and multivariate analyses were performed. Results: Age ≥40 (HR=0.33, 95% CI=0.15-0.71; p=0.0050) and changes in NLR (ΔNLR) <0.5 (HR=2.40, 95% CI-1.01-5.72; p=0.048) were independent factors predictive of longer OS. In addition, age ≥40 (HR=0.23, 95% CI=0.10-0.52; p<0.001) was an independent predictor of longer PFS. Conclusion: Changes in NLR and age ≥40 years were able to predict the efficacy of trabectedin for STS. Copyright 2021, International Institute of Anticancer Research.
Authors: Amy Barone; Dow-Chung Chi; Marc R Theoret; Huanyu Chen; Kun He; Dubravka Kufrin; Whitney S Helms; Sriram Subramaniam; Hong Zhao; Anuja Patel; Kirsten B Goldberg; Patricia Keegan; Richard Pazdur Journal: Clin Cancer Res Date: 2017-08-03 Impact factor: 12.531
Authors: Axel Le Cesne; Sara Cresta; Robert G Maki; Jean Yves Blay; Jaap Verweij; Andrés Poveda; Paolo G Casali; Carme Balaña; Patrick Schöffski; Federica Grosso; Pilar Lardelli; Antonio Nieto; Vicente Alfaro; George D Demetri Journal: Eur J Cancer Date: 2012-06-29 Impact factor: 9.162
Authors: R Garcia-Carbonero; J G Supko; J Manola; M V Seiden; D Harmon; D P Ryan; M T Quigley; P Merriam; J Canniff; G Goss; U Matulonis; R G Maki; T Lopez; T A Puchalski; M A Sancho; J Gomez; C Guzman; J Jimeno; G D Demetri Journal: J Clin Oncol Date: 2004-04-15 Impact factor: 44.544
Authors: Arnoud J Templeton; Mairéad G McNamara; Boštjan Šeruga; Francisco E Vera-Badillo; Priya Aneja; Alberto Ocaña; Raya Leibowitz-Amit; Guru Sonpavde; Jennifer J Knox; Ben Tran; Ian F Tannock; Eitan Amir Journal: J Natl Cancer Inst Date: 2014-05-29 Impact factor: 13.506
Authors: Z-Y Chen; K Raghav; C H Lieu; Z-Q Jiang; C Eng; J-N Vauthey; G J Chang; W Qiao; J Morris; D Hong; P Hoff; H Tran; D G Menter; J Heymach; M Overman; S Kopetz Journal: Br J Cancer Date: 2015-03-17 Impact factor: 7.640